On December 13, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2023). In the evening, more than 20 A-share listed companies disclosed the relevant announcements that their products were included in the national medical insurance catalog.
More than 20 A-share companies have disclosed that their products have been included in the national medical insurance catalog
On the evening of December 13, many A-share pharmaceutical companies issued an announcement that some of the company's products were included in the national medical insurance catalog.
For example, Kanghong Pharmaceutical's announcement shows that the National Medical Security Administration** issued the "Notice of the National Health Insurance Administration and the Ministry of Human Resources and Social Security on Printing and Distribution" (Yibaofa No. 30 2023) on December 13, 2023. List of Drugs for Work-related Injury Insurance and Maternity Insurance (2023).
According to the announcement issued by the pharmaceutical leader Hengrui Pharmaceutical that night, through medical insurance negotiations, repagliptin phosphate tablets, bupivacaine liposomal injection, dexmedetomidine hydrochloride nasal spray, and dexmedetomidine hydrochloride sodium chloride injection were included in the national medical insurance catalog for the first time; Apatinib mesylate tablets, pyrotinib maleate tablets, and rema** tosylate for injection were successfully renewed through the simplified renewal rules and the new indications were included in the national medical insurance catalog; Camrelizumab for injection and darsilib tablets for oxyethionate have been included in the national medical insurance catalogue through the new indications of the simplified renewal rules; Fluzoparib capsules and thiopenfilgrastim injection were successfully retained in the National Medical Insurance Catalogue through the renewal of the simplified renewal rules; The renewal of hetrombopag ethanolamine tablets was successfully retained in the National Medical Insurance Catalog; Azilsartan tablets were adjusted to regular catalog management.
According to Salubris' announcement, the company's innovative drug Salubris (generic name: alisartan cilexetil tablets, specifications of 80mg tablets and 240mg tablets respectively) has been renewed through negotiation and included in the category B scope of the national basic medical insurance, work-related injury insurance and maternity insurance drug catalogue (2023); Ennarol (generic name: ennadomat tablets, specifications of 1mg tablets, 2mg tablets, and 4mg tablets respectively) was newly included in the scope of category B of the medical insurance catalogue through negotiation.
According to the announcement of Jianxingyuan, a total of 210 products of the company and its subsidiaries are included in the "2023 National Medical Insurance Catalog", of which 95 are in Category A and 115 are in Category B. The key products included in the "2023 National Medical Insurance Catalogue" are: tobramycin inhalation solution, budesonide suspension for inhalation, levalbuterol hydrochloride nebulized inhalation solution, meropenem for injection, ilaprazole enteric-coated tablets, ilaprazole sodium for injection, leuprolide acetate microspheres for injection, triptorelin acetate microspheres for injection, fluvoxamine maleate tablets, pirobirone hydrochloride tablets, voriconazole for injection, urotropin for injection, ginsengqi Fuzheng injection, antiviral particles, etc.
Yifan Pharmaceutical announced that some of the company's products have been included in the "2023 National Medical Insurance Catalog", among which the innovative drug Aibergostim Injection and the original imported drug Dinggan Crosslinked Sodium Hyaluronate Injection are included in the negotiation for the first time, Compound Huangdai Tablets are retained in the National Medical Insurance Catalogue for simple renewal, and Maqin Cough Granules are adjusted to the regular National Medical Insurance Catalogue this time.
According to the reporter's statistics, a total of at least 20 A-share listed companies disclosed the announcement that the products were included in the national medical insurance catalogue that night.
Regarding the impact of being included in the National Medical Insurance Catalog, Hengrui Pharmaceutical said that the total sales of the company's drugs included in the National Medical Insurance Catalog in 2022 will be about 747.9 billion yuan, with total sales of about 59 percent in the first to third quarters of 2023$3 billion. The inclusion of drugs in the national medical insurance catalogue will be conducive to the sales of drugs, and the impact on the company's operating performance cannot be estimated for the time being.
Salubris said that the selection of this product into the national medical insurance catalogue fully reflects the country's support and recognition of innovative drugs with high clinical value and reasonable quality. With the implementation of the new version of the catalogue and the optimization of the "dual channel" management mechanism of negotiated drugs, it will be more conducive to marketing and sales, and contribute to the company's revenue and profit in the future.
A total of 126 new drugs have been added in this adjustment
At the press conference on the adjustment of the national basic medical insurance, work-related injury insurance and maternity insurance drug catalogue in 2023 held by the National Health Insurance Administration on December 13, Huang Xinyu, director of the Pharmaceutical Management Department of the National Health Insurance Administration, said that the application conditions for the adjustment of the national medical insurance catalogue in 2023 mainly include drugs newly listed or revised in the past five years, drugs for rare diseases, children's drugs and generic drugs encouraged by the state, and national essential drugs. After the corresponding procedures, a total of 126 new drugs have been added in this adjustment, including 21 drugs for tumors, 17 drugs for new crown and anti-infection, 15 drugs for chronic diseases such as diabetes, psychiatry, rheumatism and immunity, 15 drugs for rare diseases (among which avatinib tablets are also drugs for tumors), and 59 drugs for other fields. At the same time, 1 drug that is about to be withdrawn from the market has been transferred. After this adjustment, the total number of drugs in the catalogue will increase to 3,088, including 1,698 Western medicines and 1,390 Chinese patent medicines, and the level of protection in the fields of chronic diseases, rare diseases, and children's drugs will be further improved. In the negotiation and bidding process, a total of 143 off-list drugs participated, of which 121 were successful in negotiation and bidding, with a success rate of 846%, with an average price reduction of 617%, the success rate and ** decline are basically the same as in 2022. Combined with the negotiation of price reductions and medical insurance reimbursement factors, it is expected to reduce the burden on patients by more than 40 billion yuan in the next two years.
Long Xuewen, deputy director of the Medical Insurance Center of the National Health Insurance Administration, said that the new version of the National Medical Insurance Drug List will be officially implemented from January 1, 2024. After the issuance of the new version of the catalog, it will guide the local agencies to do a good job in the improvement of the network and information system, urge the designated medical institutions and "dual-channel" retail pharmacies to strengthen the allocation of new drugs, formulate a roadmap and inverted schedule, so that the favorable policies for the adjustment of the catalog can be implemented as soon as possible, so that the insured people can use the good drugs and new drugs included in the medical insurance catalog as soon as possible.